FORM 4

obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Check this box if no longer subject to Section 16. Form 4 or Form 5

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

					or S	Section 3	30(h) of th	è Ínvest	ment C	Company Ac	t of 1940							
1. Name and Address of Reporting Person* MAULDIN JOHN F						2. Issuer Name and Ticker or Trading Symbol GALECTIN THERAPEUTICS INC [GALT							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
					, []]]								Officer (give title			(specify	
(Last) (First) (Middle)														below)			below)	
C/O GAI	ECTIN TI	HERAPEUTICS	INC.			3. Date of Earliest Transaction (Month/Day/Year) 10/01/2013												
4960 PEACHTREE INDUSTRIAL BLVD, STE 240						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable				
(Chroch)					1									Line)				
(Street) NORCROSS GA 30071												X F	orm filed by On	e Reportin	g Pers	on		
													Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)															
		Tab	le I - N	on-Deriv	ative	Secu	rities A	cquire	d, D	isposed	of, or E	Benefic	ially Ow	ned				
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/					Execution D		3. Transaction Code (Instr. 8)					d 5) Se Be Ov	amount of curities neficially ned Following ported	Form: Di (D) or Inc	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	v	Amount	(A) or (D)	Price	Tra	nsaction(s) str. 3 and 4)			(instr. 4)	
Common Stock 10/01/20				2013			P ⁽¹⁾		376	A	\$9.96	534 ⁽²⁾	16,244	D				
Common Stock 10/02/20					013		P ⁽¹⁾		125	A	\$9.	97	16,369	D				
Common Stock														4,947	I		By Trust	
		Ta	able II							posed of converti				ed				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Executi if any			ction Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	Expir (Mon	te Exer ation I th/Day/		7. Title Amour Securi Underl Deriva Securi and 4)	nt of ties ying tive ty (Instr. 3	8. Price Derivative Security (Instr. 5)		Owner Form Direct or Ind (I) (In		11. Nature of Indirect Beneficial Ownership (Instr. 4)	
												Amount or Number						

Explanation of Responses:

- 1. The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2013.
- 2. Reflects weighted average price. Range of prices were between \$9.95 and \$9.97. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

Date

Expiration

Remarks:

/s/ Jack W. Callicutt, Attorneyin-Fact

10/03/2013

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.